Are postnatal ampicillin levels actually related to the duration of intrapartum antibiotic prophylaxis prior to delivery? A pharmacokinetic study in 120 neonates

2017 ◽  
Vol 103 (2) ◽  
pp. F152-F156 ◽  
Author(s):  
Alberto Berardi ◽  
Zaira Pietrangiolillo ◽  
Maria Letizia Bacchi Reggiani ◽  
Valentina Bianco ◽  
Daniela Gallesi ◽  
...  

ObjectiveTo assess ampicillin levels according to the duration of intrapartum antibiotic prophylaxis (IAP).DesignProspective cohort single-centre study.SettingTertiary care centre (Modena, Italy).Patients120 neonates≥35 weeks’ gestation exposed to IAP.InterventionsNeonates were divided into four groups, according to the duration of IAP prior to delivery: group 1 (n=30; <1 hour), group 2 (n=30; ≥1 and <2 hours), group 3 (n=30; ≥2 and <4 hours) and group 4 (n=30; ≥2 doses, ≥4 hours).Main outcome measuresBlood samples were collected at delivery (from the umbilical cord) and at age 4 hours (from a peripheral vessel).ResultsMedian duration of IAP was 121 min (range 7–2045 min). Median ampicillin levels in umbilical cord blood were 10.4 µg/mL (IQR 6.4–14.9) and in peripheral blood were 4.7 µg/mL (IQR 2.8–6.4µg/mL). Umbilical cord blood levels reached a peak approximately 30 min after IAP and then declined significantly (p<0.001). Peripheral blood levels did not differ among study groups. Neonates exposed to a full loading dose (n=115) had peripheral blood levels 2.5–70 times higher than the minimal inhibitory concentration for group B streptococcus. There was no relationship between neonatal ampicillin concentrations and the duration of IAP prior to delivery (β=−0.0003, 95% CI −0.02 to 0.001, p=0.680).ConclusionsAmpicillin levels reach a peak in the umbilical cord blood within 30 min of intrapartum administration. After a full loading dose, bactericidal levels persist for at least 4 hours after birth and seem independent of the duration of IAP prior to delivery.

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Tereza Pavlova ◽  
Filip Zlamal ◽  
Josef Tomandl ◽  
Zuzana Hodicka ◽  
Sumeet Gulati ◽  
...  

Irisin, an adipomyokine identified in 2012, has been investigated in association with common pregnancy complications, including gestational diabetes mellitus, preeclampsia, and intrauterine growth restriction. The objective of this study is to examine the potential role of irisin in preterm birth (PTB) by comparing its level between mothers with term and preterm labor. Maternal peripheral blood and cord blood samples were collected from 30 mothers who delivered prematurely and from 35 mothers who delivered at term. Irisin concentrations were measured in all samples using ELISA, and four common single nucleotide polymorphisms in the irisin gene were determined (rs16835198, rs726344, rs3480, and rs1746661). Univariable and multivariable regression modeling was applied to evaluate maternal and cord blood irisin concentrations in relation to preterm/term labor. Irisin concentration in umbilical cord blood was found to be associated with PTB in the univariable model (p=0.046). On the other hand, no differences in maternal blood irisin levels between mothers with preterm and term deliveries were established. To the best of our knowledge, this is the first study determining irisin levels in term and preterm deliveries in maternal peripheral blood and umbilical cord blood. Our study shows a possible association between cord blood irisin concentration and PTB occurrence.


HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 1062
Author(s):  
M. Barbosa ◽  
V. Molla ◽  
A. Mendroni Junior ◽  
M. Goncalves ◽  
E. Kimura ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
L. Herrera ◽  
S. Santos ◽  
M. A. Vesga ◽  
J. Anguita ◽  
I. Martin-Ruiz ◽  
...  

AbstractAmong hematological cancers, Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) are the most common leukemia in children and elderly people respectively. Some patients do not respond to chemotherapy treatments and it is necessary to complement it with immunotherapy-based treatments such as chimeric antigen receptor (CAR) therapy, which is one of the newest and more effective treatments against these cancers and B-cell lymphoma. Although complete remission results are promising, CAR T cell therapy presents still some risks for the patients, including cytokine release syndrome (CRS) and neurotoxicity. We proposed a different immune cell source for CAR therapy that might prevent these side effects while efficiently targeting malignant cells. NK cells from different sources are a promising vehicle for CAR therapy, as they do not cause graft versus host disease (GvHD) in allogenic therapies and they are prompt to attack cancer cells without prior sensitization. We studied the efficacy of NK cells from adult peripheral blood (AB) and umbilical cord blood (CB) against different target cells in order to determine the best source for CAR therapy. AB CAR-NK cells are slightly better at killing CD19 presenting target cells and CB NK cells are easier to stimulate and they have more stable number from donor to donor. We conclude that CAR-NK cells from both sources have their advantages to be an alternative and safer candidate for CAR therapy.


2010 ◽  
Vol 1 ◽  
pp. S60
Author(s):  
Leandro DeOliveira ◽  
Marcos Cenedeze ◽  
Rafael Larocca ◽  
Nelson Sass ◽  
Niels Olsen Câmara

2007 ◽  
Vol 29 (6) ◽  
pp. 388-392 ◽  
Author(s):  
Javier Garc??a-Castro ◽  
Antonio Balas ◽  
Manuel Ram??rez ◽  
Antonio P??rez-Mart??nez ◽  
Luis Madero ◽  
...  

2017 ◽  
Vol 80 (7) ◽  
pp. 442-451 ◽  
Author(s):  
Shih-Hui Huang ◽  
Ken-Pen Weng ◽  
Ching-Chiang Lin ◽  
Chung-Cheng Wang ◽  
Charles Tzu-Chi Lee ◽  
...  

Cytotherapy ◽  
2015 ◽  
Vol 17 (4) ◽  
pp. 418-427 ◽  
Author(s):  
Joshua Kellner ◽  
Sufang Li ◽  
Patrick A. Zweidler-McKay ◽  
Elizabeth J. Shpall ◽  
Ian McNiece

Blood ◽  
2006 ◽  
Vol 108 (10) ◽  
pp. 3360-3362 ◽  
Author(s):  
Karen M. Pastos ◽  
William B. Slayton ◽  
Lisa M. Rimsza ◽  
Linda Young ◽  
Martha C. Sola-Visner

Abstract Umbilical cord blood (CB) is a valuable source of stem cells for transplantation, but CB transplantations are frequently complicated by delayed platelet engraftment. The reasons underlying this are unclear. We hypothesized that CB- and peripheral-blood (PB)–derived megakaryocytes (MKs) respond differently to the adult hematopoietic microenvironment and to thrombopoietin (Tpo). To test this, we cultured CB- and PB-CD34+ cells in adult bone marrow stromal conditioned media (CM) or unconditioned media (UCM) with increasing concentrations of recombinant Tpo and compared the effects of these conditions on CB-versus PB-MKs. PB-MKs reached highest ploidy in response to UCM + 100 ng/mL rTpo, and the addition of CM inhibited their maturation. In contrast, CB-MKs reached highest ploidy in CM without rTpo, and high rTpo concentrations (> 0.1 ng/mL) inhibited their maturation. This is the first evidence that human neonatal and adult MKs have substantially different biologic responses to Tpo and potentially to other cytokines.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4013-4013
Author(s):  
Sean T. McCarthy ◽  
Howard Stein ◽  
Dagmar Stein ◽  
Sue Ohler ◽  
Neil A. Lachant ◽  
...  

Abstract Hemorrhagic complications occur in neonates, including intraventricular hemorrhage (IVH) in premature babies. The premature infant appears to be at greatest risk for a head bleed from days 2–3 until day 7 after birth. A relationship exists that suggests that the shorter the gestation, the greater the risk for this potentially fatal hemorrhagic event. The basis of intra-ventricular brain hemorrhage (IVH) in the premature infant is unknown. Premature birth is not necessarily the cause of IVH. The neonate is known to have a transient platelet dysfunction at the time of birth. Studies to define the transient platelet dysfunction in the neonate have been limited. Explanations in the literature include: a diminished response to physiologic agonists, defective platelet (PL) dense granule (DG) secretion, and/or ineffective mobilization of intracellular calcium in platelets. We and others have found that the adenine nucleotide content of platelets obtained from umbilical cord blood is significantly less than seen in adults. We have found that platelets obtained from umbilical cord blood have an average of 0.79±0.08 DG/PL (n=62), which is significantly decreased compared to the adult population (4–6 DG/PL) (Blood, 100(11):691a, 2002). Although the concentration of ADP and ATP were found to be decreased compared to normal adult platelets, the ATP/ADP ratio in neonatal platelets is 1.95 (n=61), consistent with established adult normal range ratio values (1.4–1.95). The current studies are ultimately intended to evaluate infants that have survived severe IVH for platelet dysfunction due to platelet dense granule deficiency (δ-SPD). Preliminary data have been obtained on peripheral blood from premature infants (n=15) obtained 3–5 d after birth. Their values (mean±2sd) are: gestational age 31±4.8 weeks and wt 1506±474 gr. The DG number (1.01±0.16/PL) is significantly decreased compared to normal adults, while the ATP (3.19±0.36 μM/1011 PL), ADP (2.63±0.54 μM/1011 PL) and ATP/ADP ratio (1.46±0.13) are normal. The decreased DG number in premature PL is strikingly similar to the DG content in cord blood PLs. We have studied one infant’s cord blood (2.41 DG/PL)and day 1 peripheral blood (3.87 DG/PL). The parents have had a normal DG number and adenine nucleotide content. These results would suggest that the premature infant platelets may have an incomplete incorporation of calcium into the dense granules 3–5 days after birth when compared to the normal adenine nucleotide content. A decrease in DG calcium would explain the decreased numbers of DGs calculated from whole mounted PLs by EM. Calcium is electron dense and if lacking in DGs, would result in an artificially low number of DGs determined by this method. To date, we have not obtained blood from a premature infant with a significant IVH or its parents to evaluate δ-SPD as a potential etiology of severe IVH.


Sign in / Sign up

Export Citation Format

Share Document